Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer

Annals of Oncology

Volumn 10, Issue 6, 1999, Pages 731-733

  Sekine, I ^a   Tamura, T ^a   Kunitoh, H ^a   Kubota, K ^a   Shinkai, T ^a   Kamiya, Y ^a   Saijo, N ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Endpoint; Non small cell lung cancer; Phase II trial; Progressive disease rate; Response rate

Indexed keywords

ASULACRINE ISETHIONATE; CARACEMIDE; CARBOPLATIN; CISPLATIN; DAUNORUBICIN DERIVATIVE; DOCETAXEL; DOXORUBICIN; EDATREXATE; EMITEFUR; EPIRUBICIN; ETOPOSIDE; FOTEMUSTINE; GEMCITABINE; IRINOTECAN; MENOGARIL; NAVELBINE; PACLITAXEL; PIRARUBICIN; RHIZOXIN; SPIROGERMANIUM; SURAMIN; TAUROMUSTINE; TENIPOSIDE; TOPOTECAN; TRIMETREXATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CORRELATION FUNCTION; DISEASE COURSE; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL INFORMATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL TIME;

EID: 0032806237     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008303921033     Document Type: Article

References (7)

1. Bonomi PD, Finkelstein DM, Ruckdeschel JC et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602-13.
2. Sekine I, Kubota K, Nishiwaki Y et al. Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer. Ann Oncol 1998; 9: 1079-84.
3. Markman M. Challenges associated with evaluating the clinical utility of non-cytotoxic pharmaceutical agents in oncology. J Cancer Res Clin Oncol 1997; 123: 581-2.
4. Eisenhauer EA. Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism. Ann Oncol 1998; 9: 1047-52.
5. World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO 1979.
6. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649 55.
7. Cvitkovic E. A call for change in anticancer drug evaluation. Eur J Cancer 1997: 33 (Suppl 2): S3-7.